Cure by Deerfield
Overview
Cure by Deerfield is a healthcare innovation ecosystem and accelerator affiliated with Deerfield Management, headquartered in New York City. It operates as an innovation campus providing laboratories, office space, mentorship, and networking to accelerate the development of healthcare solutions for startups, academic institutions, and established companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| HealthOrbit AI | Nov 2025 | Accelerator | Co-investor |
| Oben Health | Jan 2024 | Grant | Co-investor |
| Sidereal Therapeutics | May 2025 | Grant | Co-investor |
| VentriNaya | Nov 2025 | Accelerator | Co-investor |
| Pinecone Therapeutics | Nov 2025 | Accelerator | Co-investor |
For institutional investors. Book with your work email.
Key People
James Flynn
Founder
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Cure by Deerfield based?
Cure by Deerfield is headquartered in New York City, New York, United States.
When was Cure by Deerfield founded?
Cure by Deerfield was founded in 2021.
How many portfolio companies does Cure by Deerfield have?
Cure by Deerfield has 6 portfolio companies in Caplight's dataset.
What are some companies in Cure by Deerfield's portfolio?
Portfolio companies visible on Caplight include HealthOrbit AI, Oben Health, Sidereal Therapeutics, VentriNaya, Pinecone Therapeutics.
What was Cure by Deerfield's most recent investment shown here?
Cure by Deerfield's most recent investment in this portfolio sample was in VentriNaya in 2025.
What sectors does Cure by Deerfield focus on?
Cure by Deerfield focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Enterprise Software, Enterprise Software.
What company stages does Cure by Deerfield focus on?
Cure by Deerfield typically invests at the Early stage.
What is Cure by Deerfield's AUM?
Cure by Deerfield's assets under management are estimated between $15.0B and $19.1B.